Search
Ethambutol
go.drugbank.com/drugs/DB00330ApprovedInvestigational[A229048] Ethambutol was granted FDA approval on 6 November 1967.[L31663]
Cenobamate
go.drugbank.com/drugs/DB06119ApprovedInvestigational[L10653] Cenobamate was granted FDA approval on 21 November 2019.[L10653]
Albiglutide
go.drugbank.com/drugs/DB09043ApprovedInvestigationalWithdrawnAlbiglutide was approved on April 15, 2014 by the FDA.
Guanfacine
go.drugbank.com/drugs/DB01018ApprovedInvestigational[A189841] Guanfacine was granted FDA approval on 27 October 1986.[L11274]
Elafibranor
go.drugbank.com/drugs/DB05187ApprovedInvestigational[L50768] On June 10, 2024, elafibranor was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis (PBC).
Difelikefalin
go.drugbank.com/drugs/DB11938ApprovedInvestigational[A237620] Difelikefalin received FDA approval in August 2021 (under the brand name Korsuva), becoming the first FDA-approved therapy for patients with chronic kidney disease suffering from uremic pruritus … [A237620] Options for therapy are limited - with no FDA-approved treatments, off-label [gabapentin] was the most evidence-based and widely available treatment.
Sipuleucel-T
go.drugbank.com/drugs/DB06688ApprovedInvestigationalThe treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014. … Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic Hormone-Refractory Prostate Cancer (HRPC).
Delgocitinib
go.drugbank.com/drugs/DB16133ApprovedInvestigational[A264703] On July 23, 2025, delgocitinib was also granted approval by the FDA.[L53508]
Hydrocortisone
go.drugbank.com/drugs/DB00741ApprovedInvestigationalVet approved[A188420] Hydrocortisone was granted FDA approval on 5 August 1952.[L10574]
Testosterone cypionate
go.drugbank.com/drugs/DB13943ApprovedInvestigationalIt was developed by the company Pharmacia and Upjohn and FDA approved on July 25, 1979.